drugset
drugset / Trial / NCT02605811

Temozolomide in Preventing Brain Metastases in Small Cell Lung Cancer

NCT02605811 ↗

Phase 2 Unknown 426 enrolled Guangzhou Medical University
RandomizedParallel-groupOpen-labelTreatment

Summary

To investigate the response of temozolomide versus prophylactic cranial radiotherapy in preventing brain metastases in completed or partial remission limited small cell lung cancer patients.

Timeline

Start
2015-09
Primary completion
2019-12
Completion
2021-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Temozolomide Small molecule 150 mg/m2 Oral

Indications

metastatic carcinoma small cell lung carcinoma